

Supplementary materials

Table S1. Matrics WP6-1 study schedule of events

| | Screening | Baseline ^a (case & control) | | Single-blind, placebo controlled, acute dose, cross-over, randomised medication challenge ^b | | |
|--|-----------|---|----|--|----------------|----------------|
| Visit | -1 | 0a | 0b | 1 | 2 | 3 |
| Week | -4 to -1 | 0 | | 1 | 2 | 3 |
| Informed Consent / Assent | ✓ | ✓ | | | | |
| Inclusion / Exclusion Criteria | ✓ | ✓ | | | | |
| Socio-demographics | ✓ | | | | | |
| Family medical history | ✓ | | | | | |
| Medical and psychiatric history | ✓ | ✓ | | | | |
| Medication History | ✓ | | | | | |
| Current medications & Confirm washout/prohibited medicines | ✓ | ✓ | | ✓ | ✓ | ✓ |
| Physical Examination | ✓ | | | ✓ | ✓ | ✓ |
| Height | ✓ | ✓ | | | | |
| Weight | ✓ | ✓ | | ✓ | ✓ | ✓ |
| Body Temperature | ✓ | ✓ | | ✓ | ✓ | ✓ |
| Vital Signs (BP, HR) | ✓ | ✓ | | ✓ ^c | ✓ ^c | ✓ ^c |
| Pregnancy test | ✓ | ✓ | | ✓ | ✓ | ✓ |
| K-SADS | ✓ | | | | | |
| WISC-IV/WAIS-IV | ✓ | | | | | |
| TRF | ✓ | | | | | |
| YSR | ✓ | | | | | |
| CBCL | ✓ | | | | | |
| NCBRF-TIQ | ✓ | | | | | |
| MOAS | ✓ | | | | | |
| CPRS | ✓ | | | | | |
| BRIEF | ✓ | | | | | |
| ICU | ✓ | | | | | |
| CGI-S | ✓ | | | | | |
| C-GAS | ✓ | | | | | |

| Visit | -1 | 0a | 0b | 1 | 2 | 3 |
|---|----------|----|----|---|---|---|
| Week | -4 to -1 | 0 | | 1 | 2 | 3 |
| Risk assessment for pharmacological treatment | ✓ | ✓ | | ✓ | | |
| Randomization (Group A/B) | | ✓ | | | | |
| Randomization (Drug/Placebo sequence) | | | | ✓ | | |
| Drug/placebo administration | | | | ✓ | ✓ | ✓ |
| E4 wristband (HR and skin conduct) | | ✓ | ✓ | ✓ | ✓ | ✓ |
| Salivar Cortisol level | | ✓ | ✓ | ✓ | ✓ | ✓ |
| IED ^d | | ✓ | | | | |
| FEERT ^e | | ✓ | | | | |
| DD ^e | | ✓ | | | | |
| MJ ^e | | ✓ | | | | |
| PD ^e | | ✓ | | | | |
| RVIP ^d | | | ✓ | ✓ | ✓ | ✓ |
| DMS ^d | | | ✓ | ✓ | ✓ | ✓ |
| PRT ^e | | | ✓ | ✓ | ✓ | ✓ |
| NCGT ^e | | | ✓ | ✓ | ✓ | ✓ |
| FA go no go ^e | | | ✓ | ✓ | ✓ | ✓ |
| RLT ^e | | | ✓ | ✓ | ✓ | ✓ |
| ToM ^e | | | ✓ | ✓ | ✓ | ✓ |
| UG ^e | | | ✓ | ✓ | ✓ | ✓ |
| Adverse events reporting | | | | ✓ | ✓ | ✓ |

a Screening procedures have been performed on two subsequent different days within Week 0

b Only CD/ODD

c Before drug administration and after the end of the testing session

d CANTAB battery

e EMOTICOM battery